Adenosine as a modulator of brain activity

被引:64
作者
Boison, Detlev [1 ]
机构
[1] RS Dow Neurobiol Labs, Epilepsy Program, Portland, OR 97232 USA
关键词
A(1) RECEPTOR; SEIZURE SUPPRESSION; A(2A) RECEPTORS; BASAL GANGLIA; INTRATHECAL INJECTION; AMERICAN FORMULATION; IN-VIVO; KINASE; CELL; LOCALIZATION;
D O I
10.1358/dnp.2007.20.10.1181353
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
The endogenous neuromodulator adenosine controls and integrates a wide range of brain functions. Consequently, dysfunction of the adenosine system is involved in pathologies ranging from epilepsy to neurodegenerative disorders and psychiatric conditions. The adenosine system has therefore been recognized as a prime target for the development of new therapeutics for neurological diseases. This review covers the upstream and downstream targets of adenosinergic neurotransmission and provides the neurochemical rationale for the development of adenosine receptor modulating drugs (downstream) and inhibitors of adenosine kinase, the key upstream regulator of ambient levels of adenosine. Due to the unique role of adenosine to integrate and fine-tune glutamatergic and dopaminergic neurotransmission, adenosine-regulating agents have the potential to modify a wide range of downstream effects. Thus, adenosine-based therapies are rapidly evolving in preclinical and clinical studies. (c) 2007 Prous Science. All rights reserved.
引用
收藏
页码:607 / 611
页数:5
相关论文
共 65 条
[1]
The equilibrative nucleoside transporter family, SLC29 [J].
Baldwin, SA ;
Beal, PR ;
Yao, SYM ;
King, AE ;
Cass, CE ;
Young, JD .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2004, 447 (05) :735-743
[2]
Adenosine A2A receptor antagonist treatment of Parkinson's disease [J].
Bara-Jimenez, W ;
Sherzai, A ;
Dimitrova, T ;
Favit, A ;
Bibbiani, F ;
Gillespie, M ;
Morris, MJ ;
Mouradian, MM ;
Chase, TN .
NEUROLOGY, 2003, 61 (03) :293-296
[3]
Blum D, 2003, J NEUROSCI, V23, P5361
[4]
Adenosine and epilepsy: From therapeutic rationale to new therapeutic strategies [J].
Boison, D .
NEUROSCIENTIST, 2005, 11 (01) :25-36
[5]
Neonatal hepatic steatosis by disruption of the adenosine kinase gene [J].
Boison, D ;
Scheurer, L ;
Zumsteg, V ;
Rülicke, T ;
Litynski, P ;
Fowler, B ;
Brandner, S ;
Mohler, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (10) :6985-6990
[6]
Adenosine-based cell therapy approaches for pharmacoresistant epilepsies [J].
Boison, Detlev .
NEURODEGENERATIVE DISEASES, 2007, 4 (01) :28-33
[7]
Cell and gene therapies for refractory epilepsy [J].
Boison, Detlev .
CURRENT NEUROPHARMACOLOGY, 2007, 5 (02) :115-125
[8]
Adenosine kinase, epilepsy and stroke: mechanisms and therapies [J].
Boison, Detlev .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2006, 27 (12) :652-658
[9]
Chase T. N., 2003, Neurology, V61, pS107
[10]
A2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice [J].
Chen, JF ;
Huang, ZH ;
Ma, JY ;
Zhu, JM ;
Moratalla, R ;
Standaert, D ;
Moskowitz, MA ;
Fink, JS ;
Schwarzschild, MA .
JOURNAL OF NEUROSCIENCE, 1999, 19 (21) :9192-9200